Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapies that activate and amplify targeted T cells to fight cancer. The company is seeking development and commercialization partners for several of its preclinical and clinical programs.
Chimeron Bio aims to transform RNA therapy with its novel nanoparticle technology by developing new vaccines and therapies based on self-amplifying RNA for the treatment of infectious diseases, oncology and rare genetic disorders.
Building on its history of successful collaborations, the global business unit at Sanofi responsible for vaccines is seeking partners with a common drive for excellence and pursuit of innovation.
Membrane lipids have long been neglected as therapeutic targets, but Laurent Pharmaceuticals is breaking new ground with LAU-7b, a first-in-class membrane-lipid modulator for the treatment of coronavirus infection.
COVID-19 reinforced the value of infectious disease vaccines and medicines. GSK works to realise that value by putting research and development at the heart of innovation, harnessing immune science, human genetics, and advanced technologies to deliver new and specialty products.
Partnering with like-minded, focused innovators provides AstraZeneca with access to cutting-edge science and opportunities in oncology, with recent deals and an evolving partnering strategy driving its industry-leading marketed oncology portfolio.
BenchSci is on a mission to increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence (AI).
InterVenn is pioneering artificial intelligence-driven glycoproteomic analysis for novel biomarker identification to generate highly accurate diagnostics to guide targeted therapies and to fuel drug discovery and development.
With a drug discovery platform built around patient-derived induced pluripotent stem cells and multi-omics, PurMinds NeuroPharma is de-risking the path to targeted brain therapeutics.
Dompé’s Exscalate supercomputing platform is designed to accelerate drug development and is deploying an open innovation approach collaborating with top tier academic institutions, industry players and startups.
InterAx Biotech has developed a specialist drug discovery approach that combines artificial intelligence, integrated mathematical models and cell biology experiments to enable the early identification of safe and effective candidates.
Individualized cancer therapies represent the next step for cancer immunotherapy. NEC Corporation has developed cutting-edge artificial intelligence to predict patient-specific neoantigens to turn this promise into reality and extend the approach to infectious diseases.
Vyasa has developed deep-learning artificial intelligence solutions for organizations looking to solve the complex data challenges associated with healthcare and the life sciences, from improving scientific research and accelerating drug discovery and development, to enhancing care pathways.
Focusing on accelerated discovery, IBM Research is leveraging next-generation computing technologies—artificial intelligence, the hybrid cloud, and quantum computing—to streamline and optimize research in the healthcare and life sciences.
Medical AI Inc.’s technology will provide fast, accurate diagnosis of cardiac problems, kidney failure, sepsis and anemia using hospital or home electrocardiogram devices.
Nabla Bio combines innovative artificial intelligence with proprietary wet-lab biology to design, refine and optimize next-generation therapeutic antibodies.
Precision medicine company Saphetor has built the world’s largest community and knowledge base for human genome variant identification, annotation, and interpretation. Through its open access platform and its clinical and application programming interface (API)-powered bespoke implementations, Saphetor helps researchers and clinicians accelerate understanding, diagnosis, and treatment of genetic conditions.